Serum Levels of IL-6 and IL-17 in Multiple Sclerosis, Neuromyelitis Optica Patients and Healthy Subjects

Overview

Journal Int J Physiol Pathophysiol Pharmacol

Date 2020 Jan 30

PMID 31993101

Citations 18

Authors

Fereshte Ashtari

Reyhanehsadat Madanian

Vahid Shaygannejad

Sayyed Hamid Zarkesh

Keyvan Ghadimi

Affiliations

Soon will be listed here.

Abstract

Background: Studies reported that evaluating the interleukin serum level of MS and NMO patients is helpful for differentiating these two diseases from each other. This study aimed to compare the level of IL-6 and IL-17 in MS and NMO patients and healthy subjects.

Methods: This study is a case control study that evaluated the serum level of IL-6 and IL-17 in MS and NMO patients in comparison to controls in patients who referred to Kashani hospital clinics. The level of serum IL-6 and IL-17 were measured by ELISA test in all patients. Participants were divided in to three groups include MS patients, NMO patients and controls and the level of IL-6 and IL-17 were compared in this three groups.

Results: Mean of serum level of IL-6 in the NMO group was significantly lower than MS and healthy subject (P=0.02 for NMO and MS, P=0.001 for NMO and healthy subjects) but there was no significant difference between MS and healthy subjects (P=0.09). The mean of serum level of IL-17 in the MS and NMO were significantly higher than healthy subjects (P<0.001 for both). Also the mean of serum level of IL-17 in the MS was significantly higher than NMO (P=0.01). A positive significant correlation between age and serum level of IL-6 in all subjects (r=0.23, P=0.01). There was a positive significant correlation between age and serum level of IL-17 in MS and NMO patients (r=0.28, P=0.012).

Conclusion: Using IL-17 and IL-6 were inflammatory markers to diagnosis of NMO, MS and healthy subjects.

Citing Articles

Peripheral blood age-sensitive immune markers in multiple sclerosis: relation to sex, cytomegalovirus status, and treatment.

Desu H, Balthazard R, Daigneault A, Da Cal S, Klement W, Yu J EBioMedicine. 2025; 112:105559.

PMID: 39837012 PMC: 11788784. DOI: 10.1016/j.ebiom.2025.105559.

Hyperresponsiveness of Corticoid-Resistant Th17/Tc-17 Cells to TLR-2 and TLR-4 Ligands is a Feature of Multiple Sclerosis Patients at Higher Risk of Therapy Failure.

Hygino J, Sales M, Sacramento P, Kasahara T, da Silva J, Bilhao R J Inflamm Res. 2024; 17:8775-8797.

PMID: 39564547 PMC: 11573880. DOI: 10.2147/JIR.S476110.

Evaluating the Serum Level of ACTH and Investigating the Expression of miR-26a, miR-34a, miR-155-5p, and miR-146a in the Peripheral Blood Cells of Multiple Sclerosis Patients.

Al-Dahimavi S, Safaralizadeh R, Khalaj-Kondori M Biochem Genet. 2024; .

PMID: 39223335 DOI: 10.1007/s10528-024-10909-z.

Emerging imaging and liquid biomarkers in multiple sclerosis.

Gill A, Schorr E, Gadani S, Calabresi P Eur J Immunol. 2023; 53(8):e2250228.

PMID: 37194443 PMC: 10524168. DOI: 10.1002/eji.202250228.

Autoimmune Neuroinflammatory Diseases: Role of Interleukins.

Khan A, Farooq M, Hwang M, Haseeb M, Choi S Int J Mol Sci. 2023; 24(9).

PMID: 37175665 PMC: 10178921. DOI: 10.3390/ijms24097960.

References

Ishizu T, Osoegawa M, Mei F, Kikuchi H, Tanaka M, Takakura Y . Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain. 2005; 128(Pt 5):988-1002. DOI: 10.1093/brain/awh453. View

Farrokhi M, Dabirzadeh M, Dastravan N, Etemadifar M, Ghadimi K, Saadatpour Z . Mannose-binding Lectin Mediated Complement Pathway in Autoimmune Neurological Disorders. Iran J Allergy Asthma Immunol. 2016; 15(3):251-6. View

Li Y, Wang H, Long Y, Lu Z, Hu X . Increased memory Th17 cells in patients with neuromyelitis optica and multiple sclerosis. J Neuroimmunol. 2011; 234(1-2):155-60. DOI: 10.1016/j.jneuroim.2011.03.009. View

Salhofer-Polanyi S, Windt J, Sumper H, Grill H, Essmeister M, Diermayr G . Benefits of inpatient multidisciplinary rehabilitation in multiple sclerosis. NeuroRehabilitation. 2013; 33(2):285-92. DOI: 10.3233/NRE-130956. View

Uzawa A, Mori M, Ito M, Uchida T, Hayakawa S, Masuda S . Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis. J Neurol. 2009; 256(12):2082-4. DOI: 10.1007/s00415-009-5274-4. View

Monteiro C, Fernandes G, Kasahara T, Barros P, Dias A, Araujo A . The expansion of circulating IL-6 and IL-17-secreting follicular helper T cells is associated with neurological disabilities in neuromyelitis optica spectrum disorders. J Neuroimmunol. 2019; 330:12-18. DOI: 10.1016/j.jneuroim.2019.01.015. View

Ghaffari S, Nemati M, Hajghani H, Ebrahimi H, Sheikhi A, Jafarzadeh A . Circulating concentrations of interleukin (IL)-17 in patients with multiple sclerosis: Evaluation of the effects of gender, treatment, disease patterns and IL-23 receptor gene polymorphisms. Iran J Neurol. 2017; 16(1):15-25. PMC: 5506751. View

Uzawa A, Mori M, Kuwabara S . Neuromyelitis optica: concept, immunology and treatment. J Clin Neurosci. 2013; 21(1):12-21. DOI: 10.1016/j.jocn.2012.12.022. View

Dhib-Jalbut S . Pathogenesis of myelin/oligodendrocyte damage in multiple sclerosis. Neurology. 2007; 68(22 Suppl 3):S13-21. DOI: 10.1212/01.wnl.0000275228.13012.7b. View

10.

Kolls J, Linden A . Interleukin-17 family members and inflammation. Immunity. 2004; 21(4):467-76. DOI: 10.1016/j.immuni.2004.08.018. View

11.

Uzawa A, Mori M, Arai K, Sato Y, Hayakawa S, Masuda S . Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Mult Scler. 2010; 16(12):1443-52. DOI: 10.1177/1352458510379247. View

12.

Romme Christensen J, Bornsen L, Ratzer R, Piehl F, Khademi M, Olsson T . Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, Th17- and activated B-cells and correlates with progression. PLoS One. 2013; 8(3):e57820. PMC: 3585852. DOI: 10.1371/journal.pone.0057820. View

13.

Barros P, Cassano T, Hygino J, Ferreira T, Centuriao N, Kasahara T . Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase. Clin Exp Immunol. 2015; 183(3):480-9. PMC: 4750605. DOI: 10.1111/cei.12733. View

14.

Rosati G . The prevalence of multiple sclerosis in the world: an update. Neurol Sci. 2001; 22(2):117-39. DOI: 10.1007/s100720170011. View

15.

Cong H, Jiang H, Peng J, Cui S, Liu L, Wang J . Change of Th17 Lymphocytes and Treg/Th17 in Typical and Atypical Optic Neuritis. PLoS One. 2016; 11(1):e0146270. PMC: 4718616. DOI: 10.1371/journal.pone.0146270. View

16.

Sanderson P, Critchley H, Williams A, Arends M, Saunders P . New concepts for an old problem: the diagnosis of endometrial hyperplasia. Hum Reprod Update. 2016; 23(2):232-254. PMC: 5850217. DOI: 10.1093/humupd/dmw042. View

17.

Matsushita T, Tateishi T, Isobe N, Yonekawa T, Yamasaki R, Matsuse D . Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis. PLoS One. 2013; 8(4):e61835. PMC: 3630114. DOI: 10.1371/journal.pone.0061835. View

18.

Frohman E, Racke M, Van Den Noort S . To treat, or not to treat: the therapeutic dilemma of idiopathic monosymptomatic demyelinating syndromes. Arch Neurol. 2000; 57(7):930-2. DOI: 10.1001/archneur.57.7.930. View

19.

Narikawa K, Misu T, Fujihara K, Nakashima I, Sato S, Itoyama Y . CSF chemokine levels in relapsing neuromyelitis optica and multiple sclerosis. J Neuroimmunol. 2004; 149(1-2):182-6. DOI: 10.1016/j.jneuroim.2003.12.010. View

20.

Uzawa A, Mori M, Masahiro M, Kuwabara S . Cytokines and chemokines in neuromyelitis optica: pathogenetic and therapeutic implications. Brain Pathol. 2013; 24(1):67-73. PMC: 8029308. DOI: 10.1111/bpa.12097. View